stx-0119 has been researched along with Melanoma* in 1 studies
1 other study(ies) available for stx-0119 and Melanoma
Article | Year |
---|---|
NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
Constitutive activation of STAT3 can play a vital role in the development of melanoma. STAT3-targeted therapeutics are reported to show efficacy in melanomas harboring the BRAFV600E mutant and also in vemurafenib-resistant melanomas. We designed and synthesized a series of substituted nitric oxide (NO)-releasing quinolone-1,2,4-triazole/oxime hybrids, hypothesizing that the introduction of a STAT3 binding scaffold would augment their cytotoxicity. All the hybrids tested showed a comparable level of in vitro NO production. 7b and 7c exhibited direct binding to the STAT3-SH domain with IC Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Docking Simulation; Molecular Structure; Nitric Oxide; Proto-Oncogene Proteins B-raf; STAT3 Transcription Factor; Structure-Activity Relationship | 2020 |